Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.
Amrendra KumarVijay RamaniVijaya BhartiDaniel de Lima BellanNabil SalehRoman UzhachenkoChengli ShenCarlos ArteagaAnn RichmondSangeetha M ReddyAnna E VilgelmPublished in: Journal for immunotherapy of cancer (2023)
Our findings suggest that CDK4/6i-mediated DC suppression limits CD4 T-cell responses essential for the sustained activity of CD8 T cells and tumor inhibition. Furthermore, they imply that restoring DC-CD4 T-cell crosstalk via DC transfer enables effective breast cancer immunity in response to CDK4/6i and ICB treatment.